Currently, there are 31.20M common shares owned by the public and among those 30.40M shares have been available to trade.
The company’s stock has a 5-day price change of 9.38% and -16.67% over the past three months. ATNM shares are trading 11.11% year to date (YTD), with the 12-month market performance down to -73.13% lower. It has a 12-month low price of $1.10 and touched a high of $10.24 over the same period. ATNM has an average intraday trading volume of 302.84K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 10.32%, 0.24%, and -67.75% respectively.
Institutional ownership of Actinium Pharmaceuticals Inc (AMEX: ATNM) shares accounts for 29.83% of the company’s 31.20M shares outstanding.
It has a market capitalization of $43.67M and a beta (3y monthly) value of 0.14. The earnings-per-share (ttm) stands at -$1.40. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.64% over the week and 8.39% over the month.
Earnings per share for the fiscal year are expected to increase by 22.73%, and 40.31% over the next financial year.
Looking at the support for the ATNM, a number of firms have released research notes about the stock. B. Riley Securities stated their Neutral rating for the stock in a research note on August 07, 2024, with the firm’s price target at $16-$2. Stephens coverage for the Actinium Pharmaceuticals Inc (ATNM) stock in a research note released on May 14, 2024 offered a Overweight rating with a price target of $25. Cantor Fitzgerald on their part issued Overweight rating on September 08, 2022.
